Literature DB >> 34953104

Clinical Images: Severe proteinase 3 antineutrophil cytoplasmic antibody glomerulonephritis temporally associated with Sinovac Biotech's inactivated SARS-CoV-2 vaccine.

Diego Santos Garcia1, Cássio Martins1, Elissa Oliveira da Fonseca2, Victor Côrtes Pourchet de Carvalho3, Rodrigo Poubel Vieira de Rezende3.   

Abstract

Entities:  

Year:  2021        PMID: 34953104      PMCID: PMC8992465          DOI: 10.1002/acr2.11397

Source DB:  PubMed          Journal:  ACR Open Rheumatol        ISSN: 2578-5745


× No keyword cloud information.
Mass vaccination campaigns to prevent coronavirus disease 2019 (COVID‐19) are occurring worldwide; not surprisingly, reports of rare postvaccination immune‐mediated adverse events, as seen with the influenza vaccination (1), also started to surface, including cases of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after receipt of the Pfizer‐BioNTech and Moderna COVID‐19 vaccines (2, 3). Here, we report a case from Brazil of new‐onset AAV temporally associated with inactivated COVID‐19 vaccination. The patient, a previously asymptomatic 78‐year‐old White woman with a medical history of odontogenic maxillary sinusitis resolved after sinus surgery (in 2011), presented with asthenia, low‐grade fever, and a mild dry cough 2 weeks after receiving Sinovac Biotech’s COVID‐19 vaccine (CoronaVac) on March 12, 2021 (second shot on April 5, 2021). Over the weeks, in addition to persistent fever, the patient experienced worsening of fatigue, weight loss, night sweats, and renal dysfunction. Of note, various antibiotics were empirically used until she underwent a kidney biopsy on June 22. At that time, she had leukocytosis, anemia, thrombocytosis, elevated inflammatory biomarkers and serum creatinine (peak at 7.3 vs 0.8 mg/dl on May 1, 2021), cytoplasmic ANCA 1:20 by indirect immunofluorescence (reference: negative), an anti‐proteinase‐3 level of 19 U/ml by fluorescent‐enzyme immunoassay (positive >3 U/ml), a normal complement level, polyclonal hypergammaglobulinemia, and active urinary sediment. The diagnostic workup was negative for COVID‐19 (reverse transcription–polymerase chain reaction), antinuclear antibodies (ANA), rheumatoid factor, cryoglobulins, anti‐myeloperoxidase, anti‐phospholipids, anti‐Ro, anti‐La, anti‐Smith (Sm), anti–double‐stranded DNA, anti‐ribonucleoprotein (RNP), anti–glomerular basement membrane, HIV, and hepatitis B and C. Computed tomography (head, chest, paranasal sinuses, and abdomen), echocardiography, and nasal and laryngeal videoendoscopy findings were either normal or nonspecific. Urine and blood culture results were negative. The result of a kidney biopsy (14 glomeruli yielded) was compatible with necrotizing (9 of 14 glomeruli) and crescentic (cellular crescents in 6 of 14 glomeruli) glomerulonephritis. The renal biopsy specimen shows a cellular crescent and break of the glomerular basement membrane (periodic acid–Schiff stain, original magnification ×40) (A), break in Bowman’s capsule (Jones stain, original magnification ×40) (B), an acute tubular injury (hematoxylin–eosin stain, original magnification ×40) (C), and fibrinoid necrosis in the glomerulus capillary loop (hematoxylin–eosin stain, original magnification ×40) (D). Renal immunostaining results were negative for C1q; C3; immunoglobulins A, M, and G; and light chains κ and λ. The patient received high‐dose corticosteroids, pulse cyclophosphamide, and needed hemodialysis for 12 weeks. She is now controlled on low‐dose corticosteroids and mycophenolate mofetil but with chronic renal impairment. To our knowledge, this is the first report of AAV possibly triggered by an inactivated COVID‐19 vaccine. Disclosure Form Click here for additional data file.
  3 in total

1.  Post-influenza vaccination vasculitides: a possible new entity.

Authors:  Yaron Zafrir; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  J Clin Rheumatol       Date:  2009-09       Impact factor: 3.517

2.  ANCA glomerulonephritis after the Moderna COVID-19 vaccination.

Authors:  Arjun Sekar; Ruth Campbell; Jad Tabbara; Prerna Rastogi
Journal:  Kidney Int       Date:  2021-05-31       Impact factor: 10.612

3.  ANCA-Associated Vasculitis Following the Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Muhammad Tariq Shakoor; Mark P Birkenbach; Matthew Lynch
Journal:  Am J Kidney Dis       Date:  2021-07-16       Impact factor: 8.860

  3 in total
  2 in total

Review 1.  Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review.

Authors:  Eva Baier; Ulrike Olgemöller; Lorenz Biggemann; Cordula Buck; Björn Tampe
Journal:  Vaccines (Basel)       Date:  2022-04-21

2.  Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2.

Authors:  Juan Irure-Ventura; Lara Belmar-Vega; Gema Fernández-Fresnedo; Elena González-López; Carolina Castro-Hernández; Emilio Rodrigo-Calabia; Milagros Heras-Vicario; Juan Carlos Ruiz San Millán; Marcos López-Hoyos
Journal:  iScience       Date:  2022-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.